This page shows the latest Revestive news and features for those working in and with pharma, biotech and healthcare.
Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).
placebo. Natpara is NPS' second approved product after Gattex/Revestive (teduglutide), a GLP-2 analogue used for the long-term treatment of short bowel syndrome in adults that is expected to
Shire chief executive Flemming Ornskov said that the combined company would be able to drive sales of NPS' rare gastrointestinal (GI) disease therapy Gattex/Revestive (teduglutide), a GLP-2 analogue approved
is the first therapy to address the underlying mechanism of CF, and Takeda's Revestive (teduglutide) for treating adults with a rare but debilitating condition known as short bowel syndrome.
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
This is, he adds, “extremely restrictive”, and he points to Revestive (teduglutide), Shire's treatment for the rare and potentially fatal gastrointestinal disorder short bowel syndrome.
Meanwhile, the company recently won approval for a brace of new products in Europe after regulators gave the greenlight to its short bowel syndrome drug Revestive (teduglutide) in September and approved
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
There he was responsible for the commercialisation and development of Gattex/Revestive (teduglutide) for short bowel syndrome.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...